The aim of this study is to provide an in-depth analysis and forecast of the pediatric healthcare market. The focus is on scope of the market, including short-term and chronic illnesses; products and procedures currently available; and research regarding future treatments such as pharmaceuticals, diagnostics, and therapies.

Reasons for Doing The Study

Children often suffer from acute short-term illnesses such as chronic upper respiratory or ear infections, gastrointestinal illness accompanied by vomiting and diarrhea, or injury-related problems. Some children, however, develop significant chronic illnesses that last for years or for their lifetimes. Some result from genetic or inherited conditions, others from environmental factors. Prenatal care for the mother and fetus is especially important as exposure to tobacco smoke, alcohol, and other toxins can significantly affect a baby's health.

Pediatricians are confronted with a variety of short-term illnesses such as upper respiratory infections, ear infections, and gastrointestinal illnesses on a daily basis. While these illnesses are transient in nature, they also present a significant drain on time and financial resources for parents and others involved with the primary care of the child.

While most short-term illnesses are treatable and subside within 1 to 5 days, chronic illnesses are far more costly and damaging for the children, their families, and other caregivers. Chronic illnesses covered in this report include respiratory illnesses such as asthma and allergies; cystic fibrosis; diabetes; obesity; malnutrition; cerebral palsy; neurological illnesses such as attention deficient/hyperactivity disorder (ADHD), depression, and epilepsy/seizures; as well as illnesses as a consequence of low birth weight.

The report will investigate the market for treatments of acute short-term illnesses such as colds and flu, including prescription and over-the-counter medications and immunizations, and it will investigate the most significant chronic illnesses in the pediatric population. Treatment protocols and markets for products and services for each condition will be reported. The report will also identify the implications for chronic pediatric illnesses within various ethnicities including the African-American, Hispanic, and Asian communities.

Emerging technologies may be includedin the study if they appeared to be commercially significant by 2008.

Intended Audience

This study provides a broad background on the structure of the pediatric healthcare market and the chief issues it faces. IT offers the information needed to understand the current market and to address the emerging one.

This is an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investor consultants, and others interested in the pediatric healthcare market, its products, participants, and future.

Scope of Report

This report offers forecasts-by product segment-from 2008 through 2013, including supporting analyses for projections. Projections are presented in constant 2008 U.S. dollars.

Product segments covered consist of respiratory, neurological, and gastrointestinal areas, including the pharmaceuticals that accompany each market. Products within the pharmaceutical pipeline and research into alternative treatment modalities such as herbal formulations are also included. International markets are discussed, and information is provided on industry structure.

Profiles of leading companies involved with pediatric care are provided. Information on company placement within the market and strategic analyses of the company's available and emerging products is discussed.

Chapter One: Introduction
- Study Goal and Objectives
- Reasons for Doing The Study
- Intended Audience
- Scope of Report
- Information Sources
- Analyst's Credentials
- Related BCC Publications
- BCC Online Services
- Disclaimer
Chapter Two: Summary
- Projected Growth of Pediatric Markets
- Market Forecasts for Short-Term Illnesses
  - Rotavirus
  - Ear Infections
  - Upper Respiratory Infections
- Market Forecasts for Chronic Illnesses
  - Allergies
  - Attention Deficit Disorders
  - Asthma
  - Autism Spectrum Disorders
  - Diabetes
  - Obesity
Chapter Three: Overview of The Pediatric Healthcare Industry
- Prenatal Care/Implications
  - International Prenatal Care/Implications
    - Low Birth Weight
- Newborn Care
  - Care in The U S
  - International Newborn Care
    - Malnutrition
- Children Age 1 to 6
- Children Age 7 to 12
- Adolescent Children Age 13 to 18
- Adolescent Reproductive Health
  - Sexually Transmitted Diseases
    - Human Papillomavirus (Hpv)
- Vaccines/Immunizations
  - Vaccine Efficacy and Controversy
- Implications for Future Developments in The U S
Chapter Four: Short-Term Illnesses in The Pediatric Population
- Otitis Media (Ear Infections)
  - Causes of Otitis Media
    - Allergies
    - Infection
    - Blockage
    - Nutrition and Breastfeeding
  - Types and Symptoms
  - Treatment
    - Pharmacological Intervention
    - Use of Prevnar
    - Surgical Intervention
    - Myringotomy
    - Adenoidectomy and Tonsillectomy
- Gastrointestinal Illnesses
  - Rotavirus
    - Transmission
    - Symptoms
    - Treatment
    - Dehydration
    - Zinc
    - Vaccinations
    - Rotateq
    - Rotarix
  - Gastroesophageal Reflux
    - Treatment
    - Eliminate Symptoms
    - Heal Esophagus
    - Prevent Complications
- Upper Respiratory Infections
  - Causes and Symptoms
  - Treatments
    - Increased Fluid Intake
    - Second-Hand Smoke
    - Medications
  - Antibiotic Treatments
    - Withdrawing Medicines
  - Complications
Chapter Five: Chronic Illnesses in The Pediatric Population
- Cystic Fibrosis
  - Origins of The Disease
  - Diagnosing Cf
  - Prevalence
  - Treatment
    - Oscillating Positive Expiratory Pressure (Pep)
    - High-Frequency Chest Wall Oscillation (Hfcwo)
    - Medications
    - Pulmozyme
    - Tobi
    - Enzyme Treatments
    - Antibiotics
- Diabetes
  - History
  - Origins of The Disease
  - Type 1 Diabetes
  - Type 2 Diabetes
  - Complications
    - Hypoglycemia
    - Hyperglycemia
    - Ketoacidosis
  - Diagnosing Diabetes
    - Type 1 Diagnosis
    - Type 2 Diagnosis
    - Prediabetes
  - Prevalence
  - Complications of Pediatric Diabetes
    - Growth
    - Psychological Characteristics
    - Health Status
    - Family Dynamics
    - outside Care
  - Treatments
    - Glycemic Control
    - Types of Insulin
    - Long-Acting Insulins
    - Rapid Insulins
    - Intermediate-Acting Insulin
    - Short-Acting Insulin
  - Alternative Treatment for Type 2 Diabetes
    - Alternative Delivery Options
    - Insulin Pump
    - Insulin Pens
    - Inhaled Insulin
  - Oral Agents
  - Nutritional Management
  - Physical Activity
  - Glucose Monitoring Systems
    - Abbott Laboratories' New Technology
    - Pediatric Market
- Low-Birth Weight
  - Origins of The Disease
  - Prevalence
    - Consequences in The U S
    - Neurological Problems
    - Chronic Lung Disease
    - Hearing Loss
    - Retinopathy of Prematurity
  - Diagnosing Low Birth Weight
  - Treatment for Low Birth Weight
    - Retinopathy
  - Costs of Low Birth-Weight Children
- Malnutrition
  - Origins of The Disease
  - Diagnosing Malnutrition
  - Micronutrient Deficiencies
    - Vitamin A Deficiency
    - Iron Deficiency
    - Iodine Deficiency
    - Folic Acid
  - Prevalence
  - Treatments
  - Addressing Malnutrition in The U S
    - Successful National Nutrition Programs
    - Supplemental Nutrition Assistance Program (Snap)
    - Women, Infants and Children (Wic)
  - Addressing Malnutrition Globally
    - Nutriset
- Neurological Disorders
- Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder
  - Origins of Adhd
    - Brain Structures and Chemicals
    - Genetic Factors
    - Dietary Factors
  - Prevalence
  - Diagnosing Attention Deficit/Attention Deficit/Hyperactivity Disorders
  - Other Disorders
  - Treatment Types
    - Therapy
    - Pharmaceutical Treatments
    - Psychostimulant Medication
    - Non-Stimulant Medication
    - Antidepressant/Antianxiety Medications
    - Antipsychotic Medication
    - Mood Stabilizing Medication
- Global Market for Adhd Treatments
- U S. Market for Adhd Treatments
- Autism Spectrum Disorders
  - Autism
  - Asperger's Disorder
  - Childhood Disintegrative Disorder
  - Rett's Syndrome
  - Pervasive Developmental Disorder Not Otherwise Specified
  - Origins of Autism Spectrum Disorders
    - Genetics
    - Rejected Origins of Autism Spectrum Disorders
    - Environmental Factors
  - Prevalence
  - Diagnosing Asd
  - Treatment for Asd
    - Psychoeducational Treatment
    - Medical Treatment
    - Dietary Changes
    - Vitamin Therapy
    - Risperidone
  - Economic Impact of Autism
- Cerebral Palsy
  - Origins of The Disorder
  - Diagnosing Cerebral Palsy
  - Prevalence of Cp
  - Treatment of Cerebral Palsy
    - Therapies
    - Surgical Procedures
    - Medications
    - Magnesium Sulfate
- Depression
  - Origins of The Disease
    - Genetic Factors
    - Biological Factors
    - Sociological Factors
    - Psychological Factors
    - Risk Factors for Depression
    - Gender
    - Age
    - Marital Status
    - Family History
    - Parental Deprivation
    - Social Support
    - Family Type
    - Types of Depression
  - Prevalance of The Disorder
  - Diagnosing Depression
  - Treatment for Depression
    - Therapy
    - Antidepressant Medications
    - Government Warnings
- Epilepsy/Seizures
  - Origins of The Disease
    - Inherited Genetic Causes
    - Congenital Causes
    - Acquired
  - Diagnosing Epilepsy
  - Prevalence
  - Treatments
    - Anti-Epileptic Medications
    - Vagus Nerve Stimulation
    - Surgical Options
    - The Future
- Obesity
  - Origins of The Disease
  - Diagnosing Obesity
    - Genetic Factors
    - Environmental Factors
    - Behavioral Factors
  - Prevalence of The Disease
  - Treatment of Obesity
    - Healthy Food Choices
    - Dietary Restrictions
    - Increased Exercise
    - Pharmaceutical Products for Adolescents
    - Surgical Options
    - Complications
  - Global Trends
- Respiratory Illnesses
- Allergies
  - Origins of The Disease
    - Airborne Allergies
    - Food Allergies
    - Sinusitis
    - Drug Allergy
    - Allergic Rhinitis
    - Diagnosing Breathing Allergies
    - Prevalence of Allergic Rhinitis
  - Treatment
    - Immunotherapy
    - Environmental Measures
    - Antihistamines
    - Cetirizine
    - Fexofenadine
    - Desloratadine
    - Loratadine
    - Mast Cell Stabilizers
    - Anti-Ige Antibody
  - Costs
- Asthma
  - Origins of The Disease
  - Diagnosing Asthma
    - Exercise
    - Infections
    - Allergies
    - Irritants
    - Weather
    - Emotions
  - Prevalence of Asthma
  - Treatments
    - Inhaled Corticosteroids
  - Costs
Chapter Six: Current Research
- Allergies
  - Schering-Plough
    - Allergy Immunotherapy
- Asthma
  - 7tm
  - Genentech
    - Xolair
    - Anti-Il13
  - Astrazeneca
    - Medimmune
    - Anti-Il13 Mab (Cat-354)
    - Anti-Il9 Mab (Medi 528)
  - Map Pharmaceuticals
  - Schering-Plough
    - Nasal Inhaled Combinations
    - Pleconaril
  - Asthmatx
    - Bronchial Thermoplasty
  - Topigen Pharmaceuticals
  - Synairgen
  - Vectura Plc
- Attention Deficit/Attention Deficit Hyperactivity Disorder
  - Shire US
    - Intuniv
  - Somerset Pharmaceuticals
    - Selegiline
  - Cephalon
    - Modafinil
- Cerebral Palsy
  - Genetic Causes of Cp
  - Stem Cell Research
- Cystic Fibrosis
  - Gene Therapy
    - Copernicus Therapeutics
  - Infections
    - Aradigm Corp
  - Enzyme Replacement
    - Altus Pharmaceuticals
    - Eurand
  - Improved Hydration/Salt Transport
    - Lantiobio, Inc
    - Sucampo Pharmaceuticals
    - Inspire Pharmaceuticals
    - Pharmaxis
    - Gilead Sciences
  - Protein Production
    - Ptc Therapeutics
    - Vertex Pharmaceuticals
  - Inhalation Therapy
    - Vectura Plc
- Depression
  - Forest Laboratories
    - F2695
    - Lexapro
  - Sanofi Aventis
    - Saredutant
  - Sepracor
    - Sep-225289
    - Sep-227162
- Diabetes
  - Inhalation Insulin
    - Generex Biotechnology
    - Coromed, Inc
    - Nastech Pharmaceuticals
    - Mannkind Corporation
    - Map Pharmaceuticals
    - Vectura Plc
  - Transdermal Insulin Delivery
    - Dermasonics
    - Medingo
    - Vyteris
  - Blood Glucose Monitoring
    - Abbott Laboratories
  - Longer-Lasting Insulins
    - Novo Nordisk
  - Forest Laboratories
  - Combination Drug Therapies
    - Novartis/Pfizer
    - Gleevec/Sutent
    - Merck
    - Januvia/Metformin
  - Oral Diabetic Agents
    - Generex Biotechnology
- Ear Infections
- Epilepsy/Seizures
  - Ucb Pharmaceuticals
    - Brivaracetam
  - Johnson & Johnson
    - Carisbamate( Rwj-333369)
  - 2 Dioxy-D-Glucose Research
  - Sepracor
    - Eslicarbanzepine Acetate (Bia-2-093)
  - Schwarz Biosciences
    - Lacosamide
  - Jazz Pharmaceuticals
    - Jzp-4
  - Huperzine A
  - Neuroadjuvants
    - Nax-5055
    - Propylisopropylacetamide (Pid)
  - Marinus Pharmaceuticals
    - Ganaxolone
  - Valeant Pharmaceuticals
    - Retigabine
  - Taro Pharmaceuticals
    - T-2000
- Obesity
  - Drugs Marketed for Other Conditions
  - Obesity Drug Pipeline
    - Sanofi Aventis
    - Phytopharm
    - Arena Pharma
    - 7tm
Chapter Seven: Company Profiles
- 7tm Pharma A/S
  - Business Overview
  - Financial Overview
  - Products
- Abbott Laboratories
  - Abbott Laboratories
  - Financial Information
  - Products
- Altus Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Aradigm Corporation
  - Business Overview
  - Financial Information
  - Products
- Arena Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Astrazeneca Plc
  - Business Overview
  - Financials
  - Products
- Avontec Gmbh
  - Business Overview
  - Financial Information
  - Products
- Axcan Pharma USA
  - Business Overview
  - Financial Information
  - Products
- Bayer Ag (Miles-Bayer)
  - Business Overview
  - Financial Information
  - Products
- Chiesi Farmaceutici S P A
  - Business Overview
  - Financial Information
  - Products
- Copernicus Therapeutics, Inc
  - Business Overview
  - Financial Information
  - Products
- Coromed, Inc
  - Business Overview
  - Financial Information
  - Products
- Eli Lilly
  - Business Overview
  - Financial Information
  - Products
- Eurand Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Genentech Inc
  - Business Overview
  - Financial Information
  - Products
- Generex Biotechnology
  - Business Overview
  - Financial Information
  - Products
- Gilead Sciences
  - Business Overview
  - Financial Information
  - Products
- Glaxosmithkline Plc
  - Business Overview
  - Financial Information
  - Products
- Inspire Pharmaceuticals, Inc
  - Business Overview
  - Financial Information
  - Products
- Johnson & Johnson
  - Business Overview
  - Financial Information
  - Products
- Kalobios Pharmaceuticals, Inc
  - Business Overview
  - Financial Information
  - Products
- Lantibio, Inc
  - Business Overview
  - Financial Information
  - Products
- Mannkind Corp
  - Business Overview
  - Financial Information
  - Products
- Map Pharmaeuticals
  - Business Overview
  - Financial Information
  - Products
- Merck & Co Inc
  - Business Overview
  - Financial Information
  - Products
- Novartis Ag
  - Business Overview
  - Financial Information
  - Products
- Novo Nordisk
  - Business Overview
  - Financial Overview
  - Products
- Nutriset
  - Business Overview
  - Financial Overview
  - Products
- Pfizer
  - Business Overview
  - Financial Information
  - Products
- Pharmaxis, Ltd
  - Business Overview
  - Financial Informaiton
  - Products
- Phytopharm, Plc
  - Business Overview
  - Financial Information
  - Products
- Ptc Therapeutics
  - Business Overview
  - Financial Information
  - Products
- Roche Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Sanofi-Aventis
  - Business Overview
  - Fianancial Information
  - Products
- Schering-Plough
  - Business Overview
  - Financial Information
  - Products
- Sepracor
  - Business Overview
  - Financial Information
  - Products
- Shire U S
  - Business Overview
  - Financial Information
  - Products
- Solvay Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Sucampo Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Synairgen Plc
  - Business Overview
  - Financial Information
  - Products
- Topigen Pharmaceuticals Inc
  - Business Overview
  - Financial Information
  - Products
- Ucb Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Vectura Group Plc
  - Business Overview
  - Financial Information
  - Products
- Vertex Pharmaceuticals
  - Business Overview
  - Financial Information
  - Products
- Wyeth
  - Business Overview
  - Financial Information
  - Products
Appendix: Selected Pediatric Products by Illness
- List of Summaries
- Summary Table Global Trends in Pediatric Health Care, through 2013 ($ Millions)
- Summary Figure Global Trends in Pediatric Health Care, Based on Condition, 2007-2013 ($ Millions)
List of Tables
- Table 1 Projected Pediatric Preventative Care Costs from Birth through Age 18 in The U S , through 2013 ($ Millions)
- Table 2 Immunization Schedule for Children from Birth to 6 Months
- Table 3 Immunization Schedule for Children from Months to 4 to 6 Years
- Table 4 Immunization Schedule for Children and Adolescents from 7 to 18
- Table 5 Global Costs of Three Primary Short-Term Illnesses in Pediatric Population, through 2013 ($ Millions)
- Table 6 Global Prescription Costs for Treatment of Pediatric Otitis Media, through 2013 ($ Millions)
- Table 7 Prescription Costs for Treatment of Pediatric Otitis Media, in The U S , through 2013 ($ Millions)
- Table 8 Global Surgical Costs for Myringotomy in Pediatric Patients, through 2013 ($ Millions)
- Table 9 Surgical Costs for Myringotomy in U S Pediatric Patients, through 2013 ($ Millions)
- Table 10 Global Surgical Costs for Tonsillectomy/Adenoidectomy in Pediatric Patients, through 2013 ($ Millions)
- Table 11 Surgical Costs for Tonsillectomy/Adenoidectomy in U S. Pediatric Patients, through 2013 ($ Millions)
- Table 12 Global Vaccination for Pediatric Rotovirus, through 2013 ($ Millions)
- Table 13 U S. Vaccination for Pediatric Rotovirus, through 2013 ($ Millions)
- Table 14 Current Treatments for Gerd
- Table 15 Global Direct Costs of Pediatric Upper Respiratory Infections, through 2013 ($ Millions)
- Table 16 Direct Costs for Pediatric Upper Respiratory Infections in The U S, through 2013 ($ Millions)
- Table 17 Common Symptoms of An Uri
- Table 18 Global Cost of Chronic Illnesses in The Pediatric Population, through 2013 ($ Millions)
- Table 19 Cost of Chronic Illnesses in U S. Pediatric Population, through 2013 ($ Millions)
- Table 20 Global Sales for Pediatric Cystic Fibrosis Medications and Therapies, through 2013 ($ Millions)
- Table 21 U S. Sales for Pediatric Cystic Fibrosis Medications and Therapies, through 2013 ($ Millions)
- Table 22 U S. Sales for Cystic Fibrosis Medications, by Company, through 2013 ($ Millions)
- Table 23 Global Insulin Market, through 2013 ($ Millions)
- Table 24 Insulin Market in U S , through 2013 ($ Millions)
- Table 25 Insulin Approved for Children and Adolescents in The U S
- Table 26 Global Pediatric Insulin Market, through 2013 ($ Millions)
- Table 27 Pediatric Insulin Market in U S , through 2013 ($ Millions)
- Table 28 Selected List of Most Commonly Prescribed Oral Agents
- Table 29 Selected List of Companies Marketing Glucose Monitoring Tests
- Table 30 Worldwide Market for Blood Glucose Monitoring Devices, through 2013 ($ Millions)
- Table 31 U S. Blood Glucose Monitoring Market, through 2013 ($ Millions)
- Table 32 Selected Global Blood Glucose Monitoring Market by Company, through 2013 ($ Millions)
- Table 33 Global Pediatric Blood Glucose Monitoring Market, through 2013 ($ Millions)
- Table 34 U S. Pediatric Blood Glucose Monitoring Market, through 2013 ($ Millions)
- Table 35 Effects of Micronutrient Deficiencies
- Table 36 Projected Sales of Plumpy'nut, through 2013 ($ Millions)
- Table 37 Common Symptoms of Adhd
- Table 38 Additional Disorders Seen in Children with Adhd
- Table 39 Selected Prescription Medications for Treating Adhd
- Table 40 Prescription Medications for Treating Adhd, in Children under Age 18
- Table 41 Global Market for Prescription Adhd Medications, through 2013 ($ Mllions)
- Table 42 Global Market for Pediatric Prescription Adhd Medication, through 2013
- Table 43 U S. Market for Prescription Adhd Medications, through 2013 ($ Millions)
- Table 44 U S. Market for Pediatric Prescription Adhd Medications, through 2013 ($ Millions)
- Table 45 Symptoms of Autism
- Table 46 Global Direct Costs of Autism Treatments and Medications, through 2013 ($ Millions)
- Table 47 Global Direct Costs of Autism Treatments and Medications in The Pediatric Population, through 2013 ($ Millions)
- Table 48 U S. Direct Costs of Autism Treatments and Medication in Pediatric Population, through 2013 ($ Millions)
- Table 49 U S. Average Lifetime Cerebral Palsy Costs per Person, through 2013 ($ Millions)
- Table 50 Global Average Costs for Pediatric Cp Patients up to Age 18, through 2013 ($ Millions)
- Table 51 U S. Average Costs for Pediatric Cp Patients Upto Age 18, through 2013 ($ Millions)
- Table 52 Medications for Cp Patients
- Table 53 Symptoms of Depression
- Table 54 Global Direct and Indirect Cost of Depression, through 2013 ($ Billions)
- Table 55 Antidepressant Medications Appropriate for Pediatric Patients
- Table 56 Global Cost of Antidepressant Medications in Pediatric Population, through 2013 ($ Millions)
- Table 57 Cost of Antidepressant Medication in The U S Pediatric Population, through 2013 ($ Millions)
- Table 58 Potential Causes of Epilepsy, by Age
- Table 59 International Classification of Epileptic Seizures
- Table 60 Selected Current Medications for Epilepsy
- Table 61 Projected Global Direct Costs of Epilepsy Mediations, through 2013 ($ Millions)
- Table 62 Projected Global Pediatric Direct Costs of Epilepsy Medications, through 2013 ($ Millions)
- Table 63 Projected U S. Direct Costs of Epilepsy, through 2013 ($ Millions)
- Table 64 Projected Direct Costs for The U S. Pediatric Epilepsy Population, through 2013 ($ Millions)
- Table 65 Projected U S. Pediatric Direct Healthcare Costs Attributable to Overweight and Obesity, through 2013 ($ Millions)
- Table 66 Global Market for Prescription Weight Loss Products through 2013 ($ Millions)
- Table 67 Global Market for Prescription Weight Loss Products for Adolescents, through 2013 ($ Millions)
- Table 68 U S Market for Prescription Weight Loss Products for Adolescents, through 2013 ($ Millions)
- Table 69 Recommended Criteria for Bariatric Surgery for Adolescents
- Table 70 Global Market for Surgical Proceduresfor Pediatric Patients Who Are Obese/Overweight, through 2013 ($ Millions)
- Table 71 Market for Surgical Procedures for U S Pediatric Patients Who Are Obese/Overweight, through 2013 ($ Millions)
- Table 72 Projected Global Pediatric Direct Healthcare Costs Attributable to Overweight and Obesity ($ Millions)
- Table 73 Common Food Allergens
- Table 74 Common Allergy Medications Appropriate for Children
- Table 75 Global Direct Costs of Allergies, through 2013 ($ Millions)
- Table 76 Direct Costs of Allergies in The U S , through 2013 ($ Millions)
- Table 77 Global Direct Costs of Pediatric Allergies, through 2013 ($ Millions)
- Table 78 Direct Costs of U S. Pediatric Allergies, through 2013 ($ Millions)
- Table 79 Four-Step Guidelines for Treating Asthma in Children under The Age of Five
- Table 80 Four-Step Guidelines for Treating Asthma in Children over The Age of Five
- Table 81 Quick-Acting Medications for Asthma
- Table 82 Selected Listing of Inhaled Corticosteroids
- Table 83 Global Costs for Asthma Medications, through 2013 ($ Millions)
- Table 84 U S. Costs for Asthma Medications, through 2013 ($ Millions)
- Table 85 Global Costs for Pediatric Asthma Medications, through 2013 ($ Millions)
- Table 86 Costs for Pediatric Asthma Medications in The U S , through 2013 ($ Millions)
- Table 87 Selected Pediatric Products by Illness
List of Figures
- Figure 1 Global Cost of Pediatric Short-Term Illness, 2008 and 2013 ($ Millions)
- Figure 2 Projected Costs for Pediatric Chronic Illnesses in The U S , through 2013 ($ Millions)

Pharmaceutical Market Research

Pediatric Health Care Products and Services